PP
CBIO

Paloma Partners’s Crescent Biopharma CBIO Stock Holding History

Paloma Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-101
Closed -$170K – 2060
2017
Q4 		$170K Buy
+101
New +$134K ﹤0.01% 1753
2017
Q3 		– Sell
-449
Closed -$501K – 2207
2017
Q2 		$501K Buy
+449
New +$371K 0.01% 1551
2014
Q3 		– Sell
-345
Closed -$291K – 1125
2014
Q2 		$291K Buy
+345
New +$343K 0.01% 808

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Paloma Partners's CBIO Position: Q1 2018 in Review

Paloma Partners sold out of Crescent Biopharma (CBIO) in Q1 2018, closing a stake of 101 shares — an estimated $170K sold.

Paloma Partners first reported a position in CBIO in Q2 2014 and held it in 3 quarters. The position peaked at $501K in Q2 2017. 84 funds tracked by Wall St. Rank hold CBIO as of Q1 2018.

  • Paloma Partners reported no remaining Crescent Biopharma position as of Q1 2018 after selling out during the quarter.
  • Paloma Partners sold 101 Crescent Biopharma shares in Q1 2018, an estimated $170K.
  • Paloma Partners first reported a position in Crescent Biopharma in Q2 2014 and held it in 3 quarters.
  • Paloma Partners's Crescent Biopharma position peaked at $501K in Q2 2017.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2018.

Based on Paloma Partners's 13F filing for Q1 2018, filed 15 May 2018.